C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
4.000
-0.030 (-0.74%)
At close: Aug 21, 2026, 4:00 PM EDT
4.051
+0.051 (1.28%)
After-hours: Aug 21, 2026, 7:55 PM EDT
C4 Therapeutics Revenue
C4 Therapeutics had revenue of $6.64M in the quarter ending June 30, 2026, with 2.75% growth. This brings the company's revenue in the last twelve months to $35.04M, up 2.33% year-over-year. In the year 2025, C4 Therapeutics had annual revenue of $35.95M with 1.02% growth.
Revenue (ttm)
$35.04M
Revenue Growth
+2.33%
P/S Ratio
14.04
Revenue / Employee
$336,913
Employees
104
Market Cap
492.10M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.95M | 363.00K | 1.02% |
| Dec 31, 2024 | 35.58M | 4.49M | 14.43% |
| Dec 31, 2022 | 31.10M | -14.69M | -32.08% |
| Dec 31, 2021 | 45.79M | 12.59M | 37.93% |
| Dec 31, 2020 | 33.20M | 11.81M | 55.25% |
| Dec 31, 2019 | 21.38M | 2.02M | 10.42% |
| Dec 31, 2018 | 19.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 231.24M |
| Ginkgo Bioworks Holdings | 132.42M |
| Q32 Bio | 53.74M |
| Evommune | 10.00M |
| Ocugen | 4.58M |
| EyePoint | 2.79M |
CCCC News
- 12 days ago - C4 Therapeutics reports Q2 EPS (18c), consensus (23c) - TheFly
- 12 days ago - C4 Therapeutics Earnings release: Q2 2026 - Filings
- 12 days ago - C4 Therapeutics Quarterly report: Q2 2026 - Filings
- 13 days ago - C4 Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - C4 Therapeutics Transcript: AGM 2026 - Transcripts
- 2 months ago - C4 Therapeutics Transcript: KOL event - Transcripts
- 2 months ago - C4 Therapeutics Slides: KOL event - Filings
- 2 months ago - C4 Therapeutics presents further analysis from cemsidomide trial - TheFly